Definium Therapeutics (NASDAQ:DFTX) Price Target Raised to $66.00

Definium Therapeutics (NASDAQ:DFTX) had its price target boosted by Royal Bank Of Canada from $57.00 to $66.00 in a research note issued to investors on Thursday,Benzinga reports. The brokerage currently has an outperform rating on the stock.

A number of other analysts have also recently weighed in on the company. Oppenheimer reissued an “outperform” rating and issued a $70.00 price objective on shares of Definium Therapeutics in a research report on Wednesday. Citigroup reaffirmed a “buy” rating on shares of Definium Therapeutics in a research report on Monday, June 22nd. Robert W. Baird increased their price target on Definium Therapeutics from $57.00 to $75.00 and gave the company an “outperform” rating in a research note on Thursday. JonesTrading raised their price target on Definium Therapeutics from $61.00 to $74.00 and gave the stock a “buy” rating in a report on Wednesday, June 24th. Finally, Leerink Partners set a $52.00 price target on Definium Therapeutics and gave the stock an “outperform” rating in a research note on Monday, June 22nd. Two research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $62.14.

Definium Therapeutics Price Performance

Shares of DFTX opened at $42.63 on Thursday. The company has a 50 day moving average of $39.83 and a two-hundred day moving average of $26.82. The company has a quick ratio of 6.95, a current ratio of 6.95 and a debt-to-equity ratio of 0.04. Definium Therapeutics has a twelve month low of $8.70 and a twelve month high of $49.70. The company has a market cap of $5.73 billion, a price-to-earnings ratio of -12.43 and a beta of 2.23.

Definium Therapeutics (NASDAQ:DFTX) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($1.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.89). As a group, analysts predict that Definium Therapeutics will post -2.81 earnings per share for the current fiscal year.

Insider Activity at Definium Therapeutics

In related news, CFO Brandi Roberts sold 3,013 shares of the company’s stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $45.03, for a total value of $135,675.39. Following the transaction, the chief financial officer directly owned 209,487 shares of the company’s stock, valued at $9,433,199.61. This represents a 1.42% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Matthew T. Wiley sold 2,867 shares of the firm’s stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $45.03, for a total value of $129,101.01. Following the completion of the transaction, the insider owned 174,633 shares of the company’s stock, valued at $7,863,723.99. This trade represents a 1.62% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 48,096 shares of company stock valued at $2,165,763. 2.40% of the stock is currently owned by corporate insiders.

Institutional Trading of Definium Therapeutics

Several large investors have recently added to or reduced their stakes in DFTX. Russell Investments Group Ltd. raised its stake in shares of Definium Therapeutics by 110.4% in the second quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock worth $25,000 after purchasing an additional 2,003 shares during the last quarter. BNP Paribas Financial Markets boosted its position in Definium Therapeutics by 56.0% in the second quarter. BNP Paribas Financial Markets now owns 8,417 shares of the company’s stock valued at $55,000 after buying an additional 3,020 shares during the last quarter. Caxton Associates LLP purchased a new stake in Definium Therapeutics in the third quarter valued at approximately $126,000. Mercer Global Advisors Inc. ADV increased its holdings in Definium Therapeutics by 10.5% in the 3rd quarter. Mercer Global Advisors Inc. ADV now owns 21,931 shares of the company’s stock worth $259,000 after buying an additional 2,079 shares during the period. Finally, Scientech Research LLC acquired a new position in Definium Therapeutics in the 3rd quarter worth approximately $286,000. Hedge funds and other institutional investors own 27.91% of the company’s stock.

Key Definium Therapeutics News

Here are the key news stories impacting Definium Therapeutics this week:

• Positive Sentiment: Definium reported that its Phase 3 VOYAGE study of DT120 ODT in generalized anxiety disorder achieved its primary goals. The treatment produced a 5.4-point improvement on the HAM-A anxiety scale versus placebo, strengthening the case for DT120’s potential efficacy and supporting future regulatory and commercial plans. Definium Says DT120 Phase 3 GAD Study Shows 5.4-Point HAM-A Benefit vs Placebo
• Positive Sentiment: The positive clinical readout has increased confidence in additional DT120 trials and potentially supports the drug’s use across more than one indication. Investors are also watching for a further catalyst expected in September 2026. Definium Therapeutics Hits Phase 3 GAD Goals For DT120 ODT
• Positive Sentiment: Analysts raised their targets following the data: JonesTrading increased its target to $90 from $74 and maintained a Buy rating; Robert W. Baird raised its target to $75 from $57; Wells Fargo lifted its target to $72 from $68; and RBC raised its target to $66 from $57 while assigning an Outperform rating. These revisions indicate substantial perceived upside, although targets are not guarantees. Analyst price-target updates
• Positive Sentiment: Needham reportedly expects DFTX shares to rise, while recent analyst commentary broadly reflects optimism about DT120’s development prospects. Needham analyst outlook
• Neutral Sentiment: Near-term trading may remain volatile as investors assess the Phase 3 results, upcoming milestones, and expectations for third-quarter earnings. HC Wainwright Q3 earnings estimate
• Negative Sentiment: DFTX remains an unprofitable biotechnology company, and its latest reported quarter missed consensus EPS estimates. The stock’s large recent rally and elevated volatility could also encourage profit-taking despite the favorable trial news.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.